GenMark Diagnostics IncFind Ratings Reports
GENMARK DIAGNOSTICS INC's gross profit margin for the first quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. GENMARK DIAGNOSTICS INC is extremely liquid. Currently, the Quick Ratio is 3.77 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 45.91% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY16||Q1 FY15|
|Net Sales ($mil)||11.06||10.11|
|Net Income ($mil)||-12.96||-9.87|
|Balance Sheet||Q1 FY16||Q1 FY15|
|Cash & Equiv. ($mil)||37.99||70.95|
|Total Assets ($mil)||61.41||92.35|
|Total Debt ($mil)||9.56||9.5|
|Profitability||Q1 FY16||Q1 FY15|
|Gross Profit Margin||68.59||68.4|
|Return on Assets||-73.74||-42.6|
|Return on Equity||-116.95||-54.96|
|Debt||Q1 FY16||Q1 FY15|
|Share Data||Q1 FY16||Q1 FY15|
|Shares outstanding (mil)||42.79||42.13|
|Div / share||0.0||0.0|
|Book value / share||0.9||1.7|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||224668.0||203527.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 10.48 indicates a significant premium versus the S&P 500 average of 2.80 and a significant premium versus the industry average of 4.66. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, GENMARK DIAGNOSTICS INC seems to be trading at a premium to investment alternatives within the industry.
|GNMK NM||Peers 63.09||GNMK NM||Peers 32.41|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
GNMK's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
GNMK's P/CF is negative making the measure meaningless.
|GNMK NM||Peers 28.28||GNMK NA||Peers 1.04|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
GNMK's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|GNMK 10.48||Peers 4.66||GNMK -12.63||Peers 169.45|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
GNMK is trading at a significant premium to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, GNMK is expected to significantly trail its peers on the basis of its earnings growth rate.
|GNMK 10.05||Peers 4.72||GNMK 23.11||Peers 19.96|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
GNMK is trading at a significant premium to its industry.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
GNMK has a sales growth rate that exceeds its peers.